Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Cash (2021 - 2025)

Amylyx Pharmaceuticals has reported Change in Cash over the past 5 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Change in Cash at $1.5 million for Q4 2025, down 73.46% from a year ago — trailing twelve months through Dec 2025 was $148.8 million (up 261.59% YoY), and the annual figure for FY2025 was $148.8 million, up 261.59%.
  • Change in Cash for Q4 2025 was $1.5 million at Amylyx Pharmaceuticals, down from $166.6 million in the prior quarter.
  • Over the last five years, Change in Cash for AMLX hit a ceiling of $166.6 million in Q3 2025 and a floor of -$112.5 million in Q3 2023.
  • Median Change in Cash over the past 5 years was $913000.0 (2024), compared with a mean of $10.7 million.
  • Peak annual rise in Change in Cash hit 6934.5% in 2025, while the deepest fall reached 5121.08% in 2025.
  • Amylyx Pharmaceuticals' Change in Cash stood at -$26.5 million in 2021, then plummeted by 70.69% to -$45.2 million in 2022, then surged by 177.29% to $34.9 million in 2023, then tumbled by 84.1% to $5.6 million in 2024, then tumbled by 73.46% to $1.5 million in 2025.
  • The last three reported values for Change in Cash were $1.5 million (Q4 2025), $166.6 million (Q3 2025), and -$1.7 million (Q2 2025) per Business Quant data.